by Clinical Neuropsychologist | Wednesday, November 13, 2024 | Dementia
Abstract INTRODUCTION Interventions to treat speech-language difficulties in primary progressive aphasia (PPA) often use word accuracy as a highly comparable outcome. However, there are more constructs of importance to people with PPA that have received less...
by Clinical Neuropsychologist | Wednesday, November 13, 2024 | Dementia
Abstract Blood-based biomarkers continue to be explored for disease detection, monitoring of progression, and therapeutic outcomes as the diagnostic determination of Alzheimer’s Disease in Down Syndrome (DS-AD) remains challenging in clinical settings. This...
by Clinical Neuropsychologist | Wednesday, November 13, 2024 | Dementia
Abstract INTRODUCTION Pathological and neuroimaging alterations in the cerebellum of Alzheimer’s disease (AD) patients have been documented. However, the role of cerebellum-derived radiomic and structural connectome modeling in the prediction of AD progression...
by Clinical Neuropsychologist | Wednesday, November 13, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease, yet our comprehension predominantly relies on studies within non-Hispanic White (NHW) populations. Here we provide an extensive survey of the proteomic landscape of...
by Clinical Neuropsychologist | Wednesday, November 13, 2024 | Dementia
Abstract INTRODUCTION Development of Alzheimer’s disease (AD) pathology in Down’s syndrome (DS) occurs within a compressed timeline compared to sporadic or other genetic forms of AD. METHODS Plasma glial fibrillary acidic protein (GFAP) and plasma pTau-217...
